KAPA
Kairos Pharma, Ltd. (KAPA) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Very high current and quick ratios versus peers indicate ample near-term liquidity, reducing refinancing pressure despite weaker operating performance.
Net debt to EBITDA remains modest versus leveraged peers, so balance-sheet risk is contained even though profitability is currently negative.
Weaknesses
Negative ROIC versus profitable peers shows capital is not yet earning its cost, which structurally depresses valuation and reinvestment capacity.
Cash conversion cycle above 1,200 days versus peers signals severe working-capital inefficiency, tying up cash and limiting operating flexibility.
The absence of reported operating and gross margins versus peers, alongside negative returns, suggests an unproven earnings model rather than durable scale economics.
Opportunities
If working-capital intensity normalizes toward peer levels, cash release could materially improve liquidity and funding capacity over the next two to five years.
With leverage currently modest versus peers, incremental operational improvement could translate more directly into equity value than for more indebted competitors.
Threats
Persistently negative returns versus peers increase the risk that capital remains misallocated, prolonging underperformance and constraining strategic optionality.
Extreme cash-conversion lag versus peers heightens dependence on external funding or asset monetization if operating losses continue.
Peers with stronger margins and faster cash generation can outcompete on pricing and reinvestment, widening the structural gap over time.
Overall Score
KAPA’s peer positioning is weak overall because negative returns and extreme working-capital inefficiency outweigh its comparatively strong liquidity and modest leverage.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Kairos Pharma, Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
